Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres
First Claim
22. (New) An immunostimulating composition comprising encapsulating microspheres, wherein said microspheres comprise (a) a biodegradable-biocompatible poly (DL-lactide-co-glycolide) copolymer wherein said copolymer is present in an uncapped form and an end-capped form wherein a ratio of uncapped to end-capped forms is 99/1 to 1/99, and (b) an immunogenic substance which elicits production of antibodies at an intestinal mucosal surface in animal subjects to protect against infections caused by virus or bacteria.
0 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to an immunostimulating composition comprising encapsulating microspheres, which may contain a pharmaceutically-acceptable adjuvant, wherein said microspheres having a diameter between 1 nanometer (nm) to 10 microns (um) are comprised of (a) a biodegradable-biocompatible poly(DL-lactide-co-glycolide) as the bulk matrix, wherein the relative ratio between the amount of lactide and glycolide components are within the range of 40:60 to 0:100 and wherein said poly (DL-lactide-co-glycolide) is present in an uncapped form and an end-capped form wherin a ratio of uncapped to end-capped forms is 99/1 to 1/99, and (b) an immunogenic substance comprising Colony Factor Antigen (CFA/II), hepatitis B surface antigen (HbsAg), or a physiologically similar antigen that serves to elicit the producton of antibodies in animal subjects. The preparation of its composition and its use as a vaccine is also disclosed.
-
Citations
54 Claims
- 22. (New) An immunostimulating composition comprising encapsulating microspheres, wherein said microspheres comprise (a) a biodegradable-biocompatible poly (DL-lactide-co-glycolide) copolymer wherein said copolymer is present in an uncapped form and an end-capped form wherein a ratio of uncapped to end-capped forms is 99/1 to 1/99, and (b) an immunogenic substance which elicits production of antibodies at an intestinal mucosal surface in animal subjects to protect against infections caused by virus or bacteria.
-
36. (New) An immunostimulating composition comprising encapsulating microspheres, wherein said microspheres comprise (a) a biodegradable-biocompatible poly (DL-lactide-co-glycolide) as the bulk matrix, and (b) an immunogenic substance that serves to enhance spleen and Peyer'"'"'s patch B-cell responses to T &
- B-cell epitopes.
-
54. (New) An immunostimulating composition comprising encapsulating microspheres, wherein said microspheres have a diameter between 1 nanometer and 10 microns, and wherein said microspheres comprise (a) a biodegradable-biocompatible poly (DL-lactide-co-glycolide) copolymer wherein said copolymer is present in an uncapped form and an end-capped form wherein a ratio of uncapped to end-capped forms is 99/1 to 1/99, wherein the relative ratio between the amount of lactide and glycolide components are within the range of 40:
- 60 to 0;
100 and (b) an immunogenic substance comprising Colony Factor Antigen (CFA/I), Colony Factor Antigen (CFA/TT), AF/R1, hepatitis B surface antigen (HBSAg), or a physiologically similar antigen which elicits the production of antibodies at an intestinal mucosal surface in animals.
- 60 to 0;
Specification